Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

TruDiagnostic

Status and phase

Unknown

Phase 2

Conditions

Aging

Treatments

Drug: Dasatinib plus Quercetin

Study type

Interventional

Funder types

Industry

Identifiers

NCT04946383

IHB-QD-001

Details and patient eligibility

About

Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.

Full description

This is a prospective non-randomized clinical study of 20-25 patients to evaluate the effectiveness of Quercetin and Dasatinib supplements on the patient's epigenetic aging rate. The investigators predict that Quercetin and Dasatinib combined will slow cell proliferation and thus decelerate the rate of aging.

There is evidence that Quercetin and Dasatinib slows cell proliferation and decelerates aging and the risk of age-related diseases. The aim of this pilot study is to evaluate the safety, efficacy and feasibility of Quercetin and Dasatinib as an effective treatment option to improve clinical care of healthy individual's epigenetic aging rate thus prolonging longevity.

Despite considerable effort, successful treatment of reversing one's biological age has been shown to be a difficult therapeutic challenge. There is evidence that Dasatinib+Quercetin(Quercetin and Dasatinib) is a safe and effective treatment option to improve clinical care of healthy individual's biological age. Studies have shown that Dasatinib+Quercetin slows cell proliferation and decelerates aging and the risk of age-related diseases.

Enrollment

25 estimated patients

Sex

All

Ages

40+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Men and women
Ages 40 and older
Patient must be able to comply with treatment plan and laboratory tests

Exclusion criteria

Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
No immune system issues or immunodeficiency disease
No history of viral illness which could be reactivated by immune down regulation
Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke)
Diagnosis of a transient ischemic attack in the 6 months prior to screening
Patients infected with hepatitis, C or HIV
Patients with Body Mass Index (BMI) > 40 kg/m2
Presence of active infection 9. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
Unable or unwilling to provide required blood sample for testing
As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial.
If the patient has previously used Quercetin and Dasatinib.